Omeros Corporation reported its financial results for the first quarter of 2025, revealing a net loss of $33.5 million, compared to a net loss of $37.2 million in the same period in 2024. The company experienced a decrease in OMIDRIA royalties, earning $6.7 million on U.S. net sales of $22.3 million, down from $9.4 million in royalties on $31.2 million in sales during the first quarter of 2024. Total operating expenses fell to $35.0 million from $39.0 million in the previous year, attributed mainly to the conclusion of the clinical program for narsoplimab in IgA nephropathy, despite increased costs for the Phase 2 zaltenibart program. As of March 31, 2025, Omeros had $52.4 million in cash and short-term investments, a decline of $37.7 million from December 31, 2024. Interest income decreased to $1.1 million from $3.4 million in the first quarter of 2024 due to less cash and investments available for investment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.